TH287 is a selective inhibitor of the DNA repair enzyme PARP1, specifically targeting the PARP1/2 pathway with high potency. Its primary application lies in cancer research, particularly in the development of therapies for tumors with deficiencies in homologous recombination repair, such as those with BRCA1 or BR2 mutations. Due to its ability to induce synthetic lethality in these cancer cells, TH287 is used as a tool compound in preclinical studies to evaluate antitumor efficacy and mechanisms of resistance to PARP inhibition. It has shown enhanced blood-brain barrier penetration compared to earlier PARP inhibitors, making it valuable in studying brain malignancies and central nervous system involvement in cancer. Additionally, TH287 is employed in combination therapy research, where it is tested alongside DNA-damaging agents like chemotherapy or radiation to assess synergistic effects. Its use remains confined to laboratory and experimental settings, supporting the design of next-generation oncology treatments.